Gametogen

Gameto, Headquartered in New York and Boston, is a biotechnology company dedicated to transforming the impact of ovarian aging into developing solutions to enhance fertility and halt the effects of menopause on women's health. Through initial research conducted at George Church’s Lab at Harvard Medical School, Gameto has achieved groundbreaking results in creating the first human reprogrammed ovarian cells (granulosa cells and oocyte precursors) to address the issue of accelerated ovarian aging, which occurs five times faster than in any other organ in the body. Gameto is building an ovarian therapeutics platform to initially tackle menopause and improve assisted reproductive capacity through three sequential programs.